Biotech Values

[DewDiligence]

Re: GTCB IP (from Yahoo board)

>>
Nuclear-transfer and microinjection IP:
by: DewDiligence
07/19/05 08:31 am
Msg: 21335 of 21335

>>Dew, are you at all worried about this issue? "The U.S. Patent Office has entered a judgment in an interference proceeding in favor of Geron Corporation on all counts as to the priority of Geron’s patents over ACT’s U.S. Patent No. 5,945,577, which we license. ACT has also announced that it intends to appeal that decision in a proceeding in U.S. District Court."<<

GTCB’s position is that it is unencumbered by the patent dispute between ACT and GERN. Whether IP royalties for nuclear transfer are paid to ACT or to GERN does not affect GTCB’s profits or losses to any material degree. Moreover, according to Tom Newberry, nuclear-transfer IP might end up falling into the public domain if ACT’s patents were ultimately ruled invalid, and this would eliminate GTCB’s royalty obligations for products employing nuclear transfer.

ATryn is not affected whatsoever by any of the above because the ATryn herd was produced uses microinjection rather than nuclear transfer.

[Posted as a reply to: Msg 21328 by aslan2772]
<<

Please see the thread at #msg-5027284 for additional background.